PL3286311T3 - Sposób leczenia nowotworów złośliwych - Google Patents

Sposób leczenia nowotworów złośliwych

Info

Publication number
PL3286311T3
PL3286311T3 PL16769720T PL16769720T PL3286311T3 PL 3286311 T3 PL3286311 T3 PL 3286311T3 PL 16769720 T PL16769720 T PL 16769720T PL 16769720 T PL16769720 T PL 16769720T PL 3286311 T3 PL3286311 T3 PL 3286311T3
Authority
PL
Poland
Prior art keywords
malignancies
treatment
Prior art date
Application number
PL16769720T
Other languages
English (en)
Inventor
Robert H. Pierce
Adil Daud
Original Assignee
Oncosec Medical Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Incorporated filed Critical Oncosec Medical Incorporated
Publication of PL3286311T3 publication Critical patent/PL3286311T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36002Cancer treatment, e.g. tumour
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
PL16769720T 2015-03-26 2016-03-24 Sposób leczenia nowotworów złośliwych PL3286311T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562138793P 2015-03-26 2015-03-26
US201662309131P 2016-03-16 2016-03-16
EP16769720.0A EP3286311B1 (en) 2015-03-26 2016-03-24 Method for the treatment of malignancies
PCT/US2016/024079 WO2016154473A1 (en) 2015-03-26 2016-03-24 Method for the treatment of malignancies

Publications (1)

Publication Number Publication Date
PL3286311T3 true PL3286311T3 (pl) 2021-09-13

Family

ID=56978697

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16769720T PL3286311T3 (pl) 2015-03-26 2016-03-24 Sposób leczenia nowotworów złośliwych

Country Status (8)

Country Link
US (2) US10426847B2 (pl)
EP (2) EP3881860A1 (pl)
JP (2) JP6879996B2 (pl)
CA (1) CA2981049A1 (pl)
DK (1) DK3286311T3 (pl)
ES (1) ES2873093T3 (pl)
PL (1) PL3286311T3 (pl)
WO (1) WO2016154473A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6723153B2 (ja) 2013-12-05 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 生体内の望ましくない軟部組織を切除するシステム
KR102128856B1 (ko) 2015-01-30 2020-07-02 알에프이엠비 홀딩스, 엘엘씨 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템
DK3286311T3 (da) 2015-03-26 2021-05-17 Oncosec Medical Inc Fremgangsmåde til behandling af maligniteter
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3402517B1 (en) * 2016-01-15 2025-08-20 RFEMB Holdings, LLC Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
JP7287888B2 (ja) 2016-06-27 2023-06-06 ギャラリー,インコーポレイテッド ジェネレータ、電極付きのカテーテル、及び肺通路の治療方法
AU2017331275A1 (en) * 2016-09-23 2019-05-16 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
DK4218641T3 (da) 2017-12-26 2025-08-18 Galvanize Therapeutics Inc Optimering af energilevering til forskellige anvendelser
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對tigit之單域抗體及其變異體
WO2019136305A1 (en) * 2018-01-04 2019-07-11 Neumedicines Inc. Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
JP7551648B2 (ja) 2019-04-18 2024-09-17 ガルヴァナイズ セラピューティクス,インコーポレイテッド 異常組織を治療するための器械、及びシステム、
EP3980033A4 (en) 2019-06-05 2023-08-23 Emory University PHOTOLYSIS TO UNLOCK CAGED PROTEIN-LIKE THERAPEUTIC AGENTS
AU2020314830B2 (en) 2019-07-16 2026-01-22 Galvanize Therapeutics, Inc. Treatment of the reproductive tract with pulsed electric fields
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
GB2700048B (en) 2019-09-18 2026-03-04 Aldevron Llc synthetic dna vectors and method of use
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
KR102490645B1 (ko) * 2020-07-16 2023-01-25 고려대학교 산학협력단 흡수에너지 기반 전기장 암치료 계획 시스템 및 방법
CA3207359A1 (en) * 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
JP2025515486A (ja) 2022-04-29 2025-05-15 ピュリノミア バイオテック, インコーポレイテッド 好酸球駆動性疾患及び障害を治療するための方法及び組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE371031T1 (de) 1999-06-08 2007-09-15 Uab Research Foundation Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
AU2004247071B2 (en) 2003-05-30 2010-03-11 University Of South Florida Method for the treatment of malignancies
US8802643B1 (en) * 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CA3101783C (en) * 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US8994173B2 (en) * 2013-06-26 2015-03-31 International Business Machines Corporation Solder bump connection and method of making
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
DK3286311T3 (da) 2015-03-26 2021-05-17 Oncosec Medical Inc Fremgangsmåde til behandling af maligniteter
SG10201913163PA (en) 2015-12-18 2020-03-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
AU2017331275A1 (en) 2016-09-23 2019-05-16 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy

Also Published As

Publication number Publication date
EP3286311B1 (en) 2021-05-05
US10426847B2 (en) 2019-10-01
HK1251614A1 (en) 2019-02-01
ES2873093T3 (es) 2021-11-03
JP2018509477A (ja) 2018-04-05
US20200000938A1 (en) 2020-01-02
JP6879996B2 (ja) 2021-06-02
WO2016154473A8 (en) 2017-04-20
CA2981049A1 (en) 2016-09-29
US11564999B2 (en) 2023-01-31
US20180318393A1 (en) 2018-11-08
WO2016154473A1 (en) 2016-09-29
DK3286311T3 (da) 2021-05-17
JP2021119181A (ja) 2021-08-12
EP3286311A1 (en) 2018-02-28
EP3286311A4 (en) 2018-11-21
EP3881860A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
IL279627A (en) A method for treating depression
PL3286311T3 (pl) Sposób leczenia nowotworów złośliwych
IL259783A (en) Methods of treatment of malignant diseases
ZA201802420B (en) Combination therapy for treating malignancies
EP3242947A4 (en) Method for the treatment of malignancies
ZA201803166B (en) Combination therapy for treating malignancies
SG11201607130RA (en) Combination method for treatment of cancer
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
IL259996A (en) Combinations for cancer treatment
SG11201803088PA (en) Combination therapy for treating malignancies
ZA201802088B (en) Combination therapy for treating malignancies
GB201410116D0 (en) Method of treatment
IL253028A0 (en) treatment method
GB201602802D0 (en) Method of treatment
SG11201706885RA (en) Novel treatment method
PL2937084T3 (pl) Sposób leczenia hipercholesterolemii
GB201512139D0 (en) Methods of treatment
HK1262105A1 (en) Methods of treatment of malignancies
GB201511017D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201421980D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment